Original news and analysis on international IP policy
NEW YORK -- A range of speakers, including top health officials from both a developed and developing country, last week laid out the case for why the world’s leaders must now launch a shift in the way medicines all populations need are developed and priced. The need for global collaboration is clear, speakers said, but who will lead?
The renegotiation of the North American Free Trade Agreement’s (NAFTA’s) standards on patents is not good news for Canada. Any give by Canada will be costly not only to our health care system, but also to Canadian innovators, write Jean-Frédéric Morin and Richard Gold.
3D printing used to be an expensive product design tool, but it is quickly becoming an affordable and accessible technology. First emerging in the 1980s, the availability of low-cost, high-performance 3D printers has put the technology firmly within reach of consumers. While this provides a number of opportunities for designers and manufacturers, there is also concern around the impact on IP rights, writes Jia Li.
An event on 17 July at the United Nations in New York will address the "UN Secretary General's High-Level Panel on Access to Medicines: Advancing Health-Related SDGs through Policy Coherence."
A new project that stimulates the development of affordable and effective drug regimens to treat tuberculosis (TB) is catching notice in policy circles.
Access to artificial intelligence, big data, FinTech, eHealth, and digital connectivity are increasingly providing individuals around the world with access to vital resources such as employment opportunities, online banking and healthcare, according to a United Nations report released today.
The main winners of innovation are technologies that enable market application, with gene editing and artificial intelligence as two examples, Francis Gurry, director general of the World Intellectual Property Organization, told a panel discussion last week. Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), said at the same event that everybody benefits from innovation.
Access to affordable and quality medicines for all is one of the major commitments of the World Health Organization, and its new medicines and health products strategic framework for the next 15 years calls for new research and development (R&D) models, including delinkage of the R&D costs from the price of products, and fair pricing.
Tuberculosis is still a deadly killer, and a new report by two humanitarian organisations raises alarm on poor progress on the disease diagnosis and treatment. The report calls for governments to increase efforts to fight the disease, and for the G20 countries to mobilise funds to help, in particular to boost research and development for new treatments. Separately, the World Health Organization issued a call for new treatments to fight antibiotic resistant gonorrhoea.
On the eve of the G20 meeting in Hamburg, Germany, German politicians described positions on free trade and climate as the most difficult issues. Expectations from civil society groups in the G20 results are modest at best and the 6 July protest march “Welcome to Hell” was cancelled after clashes between the police and parts of the protestors.